By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Quest PharmaTech Inc. 

9411 20 Avenue

Edmonton  Alberta  T6N 1E5  Canada
Phone: 780-448-1400 Fax: 780-416-0324



Company News
Quest PharmaTech Inc. Announces Funding Support From National Research Council's Industrial Research Assistance Program For Ige Antibody Cancer Immunotherapy Development (Allergooncology) 1/13/2015 10:19:16 AM
Quest PharmaTech Inc. Completes Patient Enrollment In Phase 2b Study Of Oregovomab For The Immunotherapy Of Ovarian Cancer 6/10/2014 8:58:58 AM
Q&A Interview With CEO Of Quest PharmaTech Inc. (TSX.V: QPT) 1/22/2014 9:48:13 AM
Quest PharmaTech Inc. Strengthens its Antibody Immunotherapy Technology by Licensing Anti-Muc1 IGE Technology From Stanford University; Researchers to Present Late-Breaking Data at the 28th Annual Meeting of the Society For Immunotherapy of Cancer to be Held November 8 - 10, 2013 In Maryland, U.S. 11/7/2013 10:47:54 AM
Quest PharmaTech Inc. Establishes Joint Venture With Korean-Based AD Biotech Co., Ltd. to Develop Immunotherapeutic Products for Cancer 7/23/2013 10:24:21 AM
Quest PharmaTech Inc. Signs Exclusive License Agreement With University of California, Los Angeles (UCLA) for Anti - PSA IgE Technology; UCLA researchers to Present Anti - PSA IgE Preclinical Data at the 2013 American Association for Cancer Research Conference 4/9/2013 9:43:30 AM
Quest PharmaTech Inc. Enrolls 40th Patient in its Phase II Oregovomab Front-Line Chemo-Immunotherapy Clinical Trial for Ovarian Cancer in Italy and the U.S. 1/22/2013 10:32:05 AM
Quest PharmaTech Inc. Updates Progress of Phase II Oregovomab Front-Line Chemo-Immunotherapy Clinical Trial in Italy 7/10/2012 9:33:21 AM
Quest PharmaTech Inc. Initiates Phase II Oregovomab Front-Line Chemo-Immunotherapy Clinical Trial in United States 6/14/2012 11:15:55 AM
Quest PharmaTech Inc. Announces Signing of $8,000,000 Investment Agreement to Support Oregovomab Clinical Trial Programs 6/6/2012 10:23:06 AM